Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors
作者:Gibeom Nam、Jun Min Jung、Hyun-Ju Park、Seung Yeop Baek、Ki Seon Baek、Hui yeon Mok、Da Eun Kim、Young Hoon Jung
DOI:10.1016/j.bmc.2019.06.036
日期:2019.8
autoimmune disease therapeutics. In a previous study, we developed the novel HDAC6-selective inhibitor 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) and showed that it has anti-sepsis activity in vivo. In this study, we conducted structure-activity relationship (SAR) studies to optimize the activity and selectivity of HDAC6, synthesizing its derivatives with various aliphatic linker sizes and cap
几种人类疾病与组蛋白脱乙酰基酶(HDACs)介导的异常表观遗传途径有关,尤其是IIb类HDACs HDAC6,已成为神经退行性疾病和自身免疫性疾病治疗方法的引人注目的靶标。在以前的研究中,我们开发了新型的HDAC6-选择性抑制剂9a((E)-N-羟基-4-(2-苯乙烯基噻唑-4-基)丁酰胺),并显示其在体内具有防腐作用。在这项研究中,我们进行了结构-活性关系(SAR)研究,以优化HDAC6的活性和选择性,并合成具有各种脂肪族接头尺寸和帽结构的HDAC6衍生物。我们确定了6u((E)-N-羟基-3-(2-(4-氟苯乙烯基)噻唑-4-基)丙酰胺),具有纳摩尔抑制活性,对HDAC6的选择性是HDAC1的126倍。通过对HDAC亚型6u的对接分析,我们揭示了最佳脂族连接基大小的重要性,以及芳基帽基团的电子取代作用和刚性。因此,我们建议设计HDAC6选择性抑制剂的新原理。